ICP-488 Tablets
Sponsors
Beijing InnoCare Pharma Tech Co., Ltd.
Conditions
Cutaneous Lupus Erythematosus (CLE)Moderate to Severe Plaque PsoriasisPlaque Psoriasis PatientsPrimary Sjögren's Syndrome
Phase 2
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
CompletedNCT06109818
Start: 2024-01-04End: 2024-09-18Updated: 2025-02-28
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
RecruitingNCT07440537
Start: 2026-04-27End: 2027-12-01Target: 105Updated: 2026-06-08
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome
Not yet recruitingNCT07727486
Start: 2026-08-01End: 2029-03-01Target: 240Updated: 2026-07-27